NCT06647550

To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Hyundai Pharm · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Detailed description

This trial is a phase 2 study to evaluate the efficacy and safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise. This is multi-center, double-blind, placebo-controlled, parallel-group, dose-finding phase 2 study.

Conditions

• Type 2 Diabetes Mellitus (T2DM)

Interventions

Type	Name	Description
DRUG	HD-6277 100mg	PO, QD
DRUG	HD-6277 50mg	PO, QD
DRUG	HD-6277 25mg	PO, QD
DRUG	Placebo	PO, QD

Timeline

• Start date: 2024-12-12
• Primary completion: 2025-03-31
• Completion: 2026-12-31
• First posted: 2024-10-18
• Last updated: 2024-12-13

Locations

1 site across 1 country: South Korea